Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

Stopped early · Phase 1

Conditions studied: Iron Overload, Beta-Thalassemia

In brief

The purpose of this study is to assess safety and amount of the study drug in the blood after increasing doses of SP-420. The study will be conducted in patients with β-thalassemia.

Key facts

Study ID
NCT02274233
Run by
Sideris Pharmaceuticals
People needed
24
Starts
2014-10-01
Expected to finish
2015-09-01
Last updated by the study team
2015-09-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.